Arimoclomol citrate
A heat shock protein (HSP) inducer,It is potentially used in the treatment of neurodegenerative diseases and lysosomal storage diseases , aiming to alleviate disease progression and improve symptoms by enhancing cellular protein homeostasis and stress resistance.
Overview
Arimoclomol citrate is a potent oral small-molecule heat shock protein (HSP) inducer, with the functions of activating the heat shock response and enhancing cellular stress tolerance. Arimoclomol citrate can be used in the research of neurodegenerative diseases (such as amyotrophic lateral sclerosis and Huntington's disease), rare lipid metabolism diseases (such as Niemann-Pick disease type C) and cell stress-related diseases.
Synonyms: Arimoclomol citrate; BRX-220 citrate; (2R-)Arimoclomol citrate; OR-01; OR-04; BRX-220; BRX-345; Orphazyme OR-01; MY-PLY-FAH; Miplyffa; Arimoclomolum; Arimoclomol
Mol File: 368860-21-3.mol
Physicochemical Properties
Storage temp: 2-8°C
Form: Solid
Color: White to Off-white
MSDS Information
Experimental Data
Cell Experiment
Solubility in DMSO : 35 mg/mL (69.18 mM; ultrasonic co-solubilization; Hygroscopic DMSO has a significant effect on the solubility of the product, use freshly opened DMSO)
Preparing Stock Solutions：
Please choose the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; Once prepared into a solution, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and duration of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture).Use within 6 months when stored at -80°C, and within 1 month when stored at -20°C.
Pharmacodynamics
Mechanism Of Action
Similar Products
Memantine HCl
Therapy
: Central nervous system and pain
Target
: NMDAR
CAS
: 41100-52-1
MF
: C12H21N•HCl
MW
: 215.76
Pregabalin
Therapy
: Central nervous system and pain
Target
: CACNA2D1
CAS
: 148553-50-8
MF
: C8H17NO2
MW
: 159.23
Riluzole
Therapy
: Central nervous system and pain
Target
: SCNA
CAS
: 1744-22-5
MF
: C8H5F3N2OS
MW
: 234.2
Xanomeline
Therapy
: Central nervous system and pain
Target
: mAChRs; CHRM1; CHRM4
CAS
: 131986-45-3
MF
: C14H23N3OS
MW
: 281.42